Pharmacotherapy of atrial fibrillation: an old option with new possibilities.

Expert Opin Pharmacother

Heart Center Munich-Bogenhausen, Department of Cardiology and Intensive Care Unit, Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Strasse 77, 89125 Munich, Germany.

Published: April 2008

Background: Atrial fibrillation is the most common sustained arrhythmia observed worldwide. Despite modern ablative treatment options, pharmacotherapy remains the first-line therapy in patients with atrial fibrillation.

Objective: Based on recently published guidelines for the management of atrial fibrillation, the present paper reviews the current and emerging concepts of pharmacotherapy in atrial fibrillation.

Methods: A MEDLINE search was conducted using the keyword 'atrial fibrillation' and 'drug therapy'. The reviewed literature included clinical trials and published reviews as well as clinical guidelines.

Results: The mainstay of atrial fibrillation therapy is the prevention of thromboembolic events. With growing knowledge of the pathophysiology of atrial fibrillation new drug targets have been identified that promise improved outcomes in atrial fibrillation management and this will allow individual drug treatment in the near future.

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.9.6.913DOI Listing

Publication Analysis

Top Keywords

atrial fibrillation
24
pharmacotherapy atrial
8
atrial
7
fibrillation
6
fibrillation option
4
option possibilities
4
possibilities background
4
background atrial
4
fibrillation common
4
common sustained
4

Similar Publications

Purpose Of Review: This review aims to explore the clinical significance of atrial fluorodeoxyglucose (FDG) uptake observed in positron emission tomography (PET) scans, focusing on its association with atrial fibrillation (AF), cardiac sarcoidosis, and myocarditis. We discuss the implications of atrial uptake for patient management and prognosis.

Recent Findings: Recent studies have demonstrated that atrial FDG uptake is frequently present in patients with AF, particularly those with persistent AF, and is linked to increased risks of stroke and poorer outcomes after ablation.

View Article and Find Full Text PDF

Background: Heart failure (HF) is a heterogeneous clinical syndrome affecting a growing global population. Due to the high incidence of cardiovascular risk factors, a large proportion of the Western population is at risk for heart failure. Oxidative stress and inflammation play a crucial role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF).

View Article and Find Full Text PDF

Post-operative new-onset atrial fibrillation (POAF) is a possible complication following cardiac surgery. Digoxin is a drug with positive inotropic and negative chronotropic effects and is listed among antiarrhythmic drugs that can be prescribed in dogs with atrial fibrillation. This report aims at describing the use of digoxin in two dogs with persistent POAF after mitral valve repair.

View Article and Find Full Text PDF

Background: Conduction system pacing (CSP) has been reported to improve clinical outcomes in comparison of right ventricular pacing (RVP). However, the performance between CSP and RVP on the risk of new-onset atrial fibrillation (AF) remains elusive.

Methods: Four online databases were systematically searched up to July 1, 2024.

View Article and Find Full Text PDF

Neurocognitive disorders are a major public health challenge, affecting 55 million people, and are projected to triple by 2050. This year's research highlights pathological mechanisms such as mitochondrial dysfunction and brain inflammation. Modifiable risk factors, such as vision loss, underscore the importance of early prevention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!